论文部分内容阅读
目的:观察原发性乳癌新辅助化疗的临床效果及价值。方法:将自2009年8月~2012年8月在我院就诊的62例乳癌患者的临床资料进行回顾性分析,患者采用新辅助化疗后均采用Miller及Payhe方法再次进行评价。将评价结果与超声影像结果进行比较观察。结果:本组患者治疗有效且肿瘤残留≤1cm患者43例,其中显著有效21例,有效22例。经Miller及Payhe方法评价,病理显效20例;最大直径>1cm的19例患者中,显效6例,有效9例,病理显效8例,2组数据比较有显著差异,P<0.05,有统计学意义。结论:原发性乳腺癌患者行新辅助化疗后,残留病灶明显减小,且病理反应较好。
Objective: To observe the clinical effect and value of neoadjuvant chemotherapy for primary breast cancer. Methods: The clinical data of 62 patients with breast cancer who were treated in our hospital from August 2009 to August 2012 were retrospectively analyzed. After neoadjuvant chemotherapy, patients were evaluated again by Miller and Payhe methods. The evaluation results and ultrasound imaging results were observed. Results: The group of patients with effective treatment and residual tumor ≤ 1cm 43 patients, of which 21 cases were significantly effective, effective in 22 cases. According to the method of Miller and Payhe, pathological findings were significant in 20 cases and in 19 cases with maximum diameter> 1 cm, 6 cases were markedly effective, 9 cases were effective and 8 cases were pathologically significant. There was significant difference between the two groups (P <0.05) significance. Conclusion: After neoadjuvant chemotherapy, patients with primary breast cancer have significantly fewer residual lesions and better pathological response.